Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China #Publishing

San Diego, California--(Newsfile Corp. - October 4, 2026) - Recently, Kexing Biopharma (688136.SH) announced that its wholly owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), has received a Notice of Approval for Drug Clinical Trials from China's National Medical Products Administration (NMPA), authorizing the initiation of clinical trials of GB20, a proprietary investigational anti-TL1A monoclonal antibody for inflammatory bowel disease (IBD).Inflammatory bowel...


http://dlvr.it/TVmfWN

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology

International Property Alerts: Global Property Exhibition Singapore 2025 Highlights London's Best New Developments #Advertising